tirzepatide obesity nejm vs Semaglutide for – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% weight loss at 72 wks • Semaglutide: −13.7% • Greater waist reduction Tirzepatide GLP-1 medication is known

The metabolic benefits documented in the research emerge over weeks and months of regular consumption, not from occasional use

Potential side effects Using tirzepatide that hasn't been stored correctly may increase the risk of adverse reactions or unexpected side effects

Many patients starting their weight-loss journey ask whether a lower 5mg dose can deliver meaningful results, or if higher doses are necessary for success

Some of these symptoms include fever, lower back pain, irregular periods, frequent urination, and pelvic pain

If you swap out a mid-afternoon biscuit, bag of crisps, or seed-oil-heavy snack for a handful of macadamias, the metabolic maths shifts heavily in your favour

Nel paziente con pressione iniziale normale, il calo di peso pu portare i valori in un range basso-normale (per esempio 100/65), con qualche sintomo ortostatico nelle prime settimane